olga capdevila pons

Dr. olga capdevila pons


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2025 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
PVPaola Vidal-Montal
Paola Vidal-Montal
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
FOFrancesc Xavier Fulladosa Oliveras
Francesc Xavier Fulladosa Oliveras
FMFrancesca Mitjavila
Francesca Mitjavila
OPolga capdevila pons
olga capdevila pons
JNJoan M Nolla
Joan M Nolla
Objective: To investigate the rate and factors influencing renal relapse (RR) in proliferative lupus nephritis (LN) patients who discontinued immunosuppressive therapy (IST), as well as the long-term renal outcomes following RR. Methods: Retrospective, single-centre study of biopsy-confirmed LN patients who had received IST for at least 36 months and maintained complete renal response (CRR) for a minimum of 12 months before therapy discontinuation. Results: Of a total of 106 patients meeting the inclusion criteria, 76 with proliferative classes were selected for analysis. The median duration of IST prior to discontinuation was 83.5 months (IQR 25th–75th: 53.5–120). Relapse occurred in 29 patients (38.2%) at a median of 26.5 months (IQR 25th–75th: 9.25–63.5 months) following IST withdrawal. Relapses were classified as severe in 9 cases (31%) and moderate in 16 cases (55.2%). Renal rebiopsy was performed in 25 of these patients (86.2%), with 80% retaining the same histological class. Discontinuation of IST at ≤34 years of age significantly increased the risk of RR (adjusted HR: 3.5). In contrast, an IST duration exceeding 48 months prior to discontinuation (HR: 0.26), maintaining CRR for at least 48 months (HR: 0.32), achieving complete remission per DORIS (definition of remission in systemic lupus erythematosus) criteria at IST withdrawal (HR: 0.21) and gradual IST tapering (HR: 0.09) were associated with a reduced risk of RR. Following reintroduction of IST, 20 out of 29 patients (68.9%) achieved CRR, 5 (17.2%) achieved a partial response and 4 (13.8%) did not respond; of these, 3 patients (10.3%) progressed to end-stage renal disease. Conclusions: Successful withdrawal of IST is possible in carefully selected patients with proliferative LN. If an RR occurs, most patients are able to remain in remission after resuming IST.

25 July 2023 in Medicina
Verified
Journal Article
Open access
PDF file
OPolga capdevila pons
olga capdevila pons
FMF. Mitjavila
F. Mitjavila
Gerard EspinosaGerard Espinosa
Gerard Espinosa
LCLuis Caminal-Montero
Luis Caminal-Montero
AMA. Marín-Ballvè
A. Marín-Ballvè
GRGuillermo Ruiz-Irastorza
Guillermo Ruiz-Irastorza
Objectives: To analyze the characteristics and the predictive factors of the use of rituximab and belimumab in daily practice in patients from the inception cohort Registro Español de Lupus (RELES). Material and methods: The study included 518 patients. We considered patients treated with biologics who received at least one dose of rituximab or belimumab, and possible indications of those manifestations registered at the same time or in the previous 2 months of the start of the therapy. Results: In our cohort, 37 (7%) patients received at least one biological treatment. Rituximab was prescribed in 26 patients and belimumab in 11. Rituximab was mainly prescribed for hemolytic anemia or thrombocytopenia (11 patients, 42%), lupus nephritis and neuropsychiatric lupus (5 patients each, 19%). Belimumab was mostly used for arthritis (8 patients, 73%). In the univariate analysis, the predictive factors at diagnosis for the use of biologic therapy were younger age (p = 0.022), a higher SLEDAI (p = 0.001) and the presence of psychosis (p = 0.011), organic mental syndrome (SOCA) (p = 0.006), hemolytic anemia (p = 0.001), or thrombocytopenia (p = 0.01). In the multivariant model, only younger age, psychosis, and hemolytic anemia were independent predictors of the use of biologics. Conclusions: Rituximab is usually given to patients with hematological, neuropsychiatric and renal involvement and belimumab for arthritis. Psychosis, hemolytic anemia and age at the diagnosis of lupus were independent predictive factors of the use of biological agents. Their global effects are beneficial, with a significant reduction in SLE activity and a low rate of side effects.

21 March 2026 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PVPaola Vidal-Montal
Paola Vidal-Montal
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
FMFrancesca Mitjavila
Francesca Mitjavila
FOFrancesc Xavier Fulladosa Oliveras
Francesc Xavier Fulladosa Oliveras
OPolga capdevila pons
olga capdevila pons
JNJoan M Nolla
Joan M Nolla
To evaluate the prevalence, associated factors, and prognostic performance of NIH activity index–defined interstitial inflammation (NIH-TII) and interstitial fibrosis and tubular atrophy (IFTA) in lupus nephritis (LN). This retrospective cohort study analyzed 195 renal biopsy episodes from 135 LN patients. Tubulointerstitial lesions were graded according to histopathological severity. NIH-TII was assessed semiquantitatively using the interstitial inflammation component of the modified NIH activity index. Among 195 renal biopsies, class IV LN was most frequent (49.2%). Tubulointerstitial involvement was present in 74.3% of cases, with isolated NIH-TII in 14.4%, isolated IFTA in 15.9%, and both in 44.1%. Moderate-to-severe NIH-TII and IFTA were observed in 11.3% and 15.9% of biopsies, respectively. Patients with moderate-to-severe NIH-TII were older, had worse renal function, and more frequently exhibited moderate-to-severe IFTA. Moderate-to-severe IFTA was associated with older age, longer SLE duration, prior LN episodes, higher chronicity index, and impaired renal function, and was strongly associated with non-renal response and ESRD progression. In multivariable logistic regression, prior LN episodes (OR 8.4) and moderate-to-severe IFTA (OR 4.92) predicted non-renal response. In multivariable Cox regression, prior LN episodes (HR 8.55), moderate-to-severe IFTA (HR 8.93), and thrombotic microangiopathy (HR 12.99) predicted ESRD progression. Longitudinal analyses showed frequent progression of IFTA over time with increasing chronicity index. Moderate-to-severe IFTA was a strong predictor of renal non-response and ESRD progression. TII defined according to the NIH activity index, which does not include systematic assessment of tubulitis or total cortical inflammatory burden, was not independently associated with outcomes. The online version contains supplementary material available at 10.1186/s13075-026-03799-6.

1 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MRManuel Rubio-Rivas
Manuel Rubio-Rivas
MRMar Ronda
Mar Ronda
APARIADNA PADULLES-ZAMORA
ARIADNA PADULLES-ZAMORA
FMFrancesca Mitjavila
Francesca Mitjavila
ARAntoni Riera-Mestre
Antoni Riera-Mestre
XCXavier Corbella
Xavier Corbella
Introduction: On the basis of the preliminary report from the RECOVERY trial, the use of dexamethasone or alternative corticosteroids (CS) is currently recommended in severe COVID-19 patients requiring supplemental oxygen. However, last updated recommendations have not taken a position either for or against the use of other immunomodulators such as tocilizumab (TCZ), with or without CS, since results are still limited. Methods: From March 17 to April 7, 2020, a real-world observational retrospective analysis was conducted at our 750-bed university hospital to study the characteristics and risk factors for mortality in patients with severe COVID-19 treated with TCZ +/-CS, in addition to standard of care (SOC). Data were obtained from routine clinical practice, stored in electronic medical records. The main outcome was all-cause in-hospital mortality. Results: A total of 1,092 COVID-19 patients were admitted during the study period. Of them, 186 (17%) were treated with TCZ, of which 129 (87.8%) in combination with CS. Of the total 186, 155 (83.3 %) patients were receiving non-invasive ventilation when TCZ +/-CS was initiated. Mean time from symptoms onset and hospital admission to TCZ use was 12 (± 4.3) and 4.3 days (± 3.4), respectively. Overall, 147 (79%) survived and 39 (21%) died. By multivariate analysis, mortality was associated with older age (HR=1.09, p<0.001), chronic heart failure (HR=4.4, p=0.003), and chronic liver disease (HR=4.69, p=0.004). The use of CS, in combination with TCZ, was the main protective factor against mortality (HR=0.26, p<0.001) in such severe COVID-19 patients receiving TCZ. No serious superinfections were observed after a 30-day follow-up. Conclusions: In severe COVID-19 patients receiving TCZ due to systemic host-immune inflammatory response syndrome, the use of CS in addition to TCZ therapy, showed beneficial effect in preventing in-hospital mortality.

20 July 2026 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
VMVictor Moreno-Torres
Victor Moreno-Torres
ARAna Royuela
Ana Royuela
GTGuillem Policarpo Torres
Guillem Policarpo Torres
DRDiana Paredes Ruiz
Diana Paredes Ruiz
MCMaría Calabuig
María Calabuig
O(on behalf of the Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI)
on behalf of the Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI)
Objectives: To evaluate the dynamics of C3, C4 and anti-dsDNA antibody levels and their association with clinical activity and flares in patients with systemic lupus erythematosus (SLE) treated with belimumab (BEL). Methods: Retrospective longitudinal cohort study from the BELILES-GEAS registry. Serological markers were assessed at the time of SLE diagnosis, at baseline, at each follow-up visit (months 3, 6, 12, 18, and 24 after treatment initiation) and during disease flares. Results: A total of 371 patients were included, with a median drug exposure of 13.2 months. At baseline, 70.1% of patients were seropositive. SLE Disease Activity Index 2000 (SLEDAI-2K) and cSLEDAI scores and prednisone doses decreased significantly over time, whereas serum C3 and C4 levels, anti-dsDNA positivity and immunosuppressant use remained stable. Among 95 (25.6%) patients who experienced 139 (14.5%) flares, longitudinal analysis adjusted by immunosuppressant use and prednisone dose revealed no association between flare occurrence and low C3 or C4, whereas anti-dsDNA antibody positivity was (C3 OR=1.31, 95% CI 0.82 to 2.09; C4 OR=1.08, 95% CI 0.62 to 1.86, and anti-dsDNA OR=1.81, 95% CI 1.09 to 3.01, respectively). When stratified by flare severity, low C3 levels showed a borderline association with moderate-to-severe flares (OR=1.82, 95% CI 0.99 to 3.31), while no significant associations were observed for C4 or for mild flares. There was no association between serum level of C3 or C4 and cSLEDAI. The flare-discriminative performance of SLEDAI-2K and cSLEDAI was similar (AUC-ROCs 0.779 vs 0.781, p=0.88). Conclusion: In SLE patients treated with BEL, the clinical utility of serological markers appears dissociated from disease activity. While C3 and C4 levels were not clearly related to disease activity or flares, low C3 levels showed a borderline association with moderate-to-severe flares, and anti-dsDNA positivity remained associated with increased flare risk, supporting a clinical assessment–driven approach with complementary use of anti-dsDNA.

12 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
XSXavier Solanich
Xavier Solanich
AAA Antolí
A Antolí
NPN Padullés
N Padullés
MFMarta Fanlo-Maresma
Marta Fanlo-Maresma
AIA Iriarte
A Iriarte
XCXavier Corbella
Xavier Corbella
Introduction Some COVID-19 patients evolve to severe lung injury and systemic hyperinflammatory syndrome triggered by both the coronavirus infection and the subsequent host-immune response. Accordingly, the use of immunomodulatory agents has been suggested but still remains controversial. Our working hypothesis is that methylprednisolone pulses and tacrolimus may be an effective and safety drug combination for treating severe COVID-19 patients. Methods and analysis TACROVID is a randomized, open-label, single-center, phase II trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) versus SoC alone, in patients at advanced stage of COVID-19 disease with lung injury and systemic hyperinflammatory response. Patients are randomly assigned (1:1) to one of two arms (42 patients in each group). The primary aim is to assess the time to clinical stability after initiating randomization. Clinical stability is defined as body temperature ≤ 37.5°C, and PaO2/FiO2 > 400 and/or SatO2/FiO2 > 300, and respiratory rate ≤24 rpm; for 48 consecutive hours. Discussion Methylprednisolone and tacrolimus might be beneficial to treat those COVID-19 patients progressing into severe pulmonary failure and systemic hyperinflammatory syndrome. The rationale for its use is the fast effect of methylprednisolone pulses and the ability of tacrolimus to inhibit both the CoV-2 replication and the secondary cytokine storm. Interestingly, both drugs are low-cost and can be manufactured on a large scale; thus, if effective and safe, a large number of patients could be treated in developed and developing countries. Trial registration number NCT04341038 / EudraCT: 2020-001445-39